Key Points
- Director purchase: Joseph Slattery bought 16,000 shares on Dec. 24 at an average price of $5.99 for a total of $95,840, and the transaction was filed with the SEC.
- Stock and analyst context: Shares rose about 10.5% and opened at $6.41 (market cap $71.66M), but the company posted a sizeable EPS miss (‑$2.91 vs. ‑$1.47) and the consensus analyst rating is "Hold" with a $26.50 target.
- Institutional interest and business focus: Multiple funds built new Q3 positions (about 75% of stock held by institutions), and ImageneBio is a clinical‑stage biotech developing IMG‑007 after rebranding from Ikena Oncology.
ImageneBio, Inc. (NASDAQ:IMA - Get Free Report) Director Joseph Slattery purchased 16,000 shares of the business's stock in a transaction on Wednesday, December 24th. The shares were purchased at an average price of $5.99 per share, with a total value of $95,840.00. Following the completion of the purchase, the director owned 16,000 shares in the company, valued at approximately $95,840. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
ImageneBio Stock Up 10.5%
Shares of NASDAQ:IMA opened at $6.41 on Tuesday. The stock has a market capitalization of $71.66 million, a PE ratio of -0.79 and a beta of 0.44. The firm's 50 day moving average price is $7.21 and its 200-day moving average price is $10.98. ImageneBio, Inc. has a twelve month low of $5.70 and a twelve month high of $20.40.
ImageneBio (NASDAQ:IMA - Get Free Report) last announced its earnings results on Wednesday, November 12th. The company reported ($2.91) EPS for the quarter, missing analysts' consensus estimates of ($1.47) by ($1.44). Analysts expect that ImageneBio, Inc. will post -0.91 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several analysts have issued reports on IMA shares. Weiss Ratings began coverage on ImageneBio in a report on Wednesday, October 22nd. They set a "sell (e-)" rating for the company. Zacks Research cut ImageneBio from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 29th. Wedbush lowered shares of ImageneBio from a "neutral" rating to an "underperform" rating in a report on Tuesday, November 25th. Leerink Partnrs raised shares of ImageneBio to a "strong-buy" rating in a report on Friday, October 24th. Finally, Leerink Partners assumed coverage on shares of ImageneBio in a research report on Friday, October 24th. They issued an "outperform" rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $26.50.
Read Our Latest Report on ImageneBio
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. Deep Track Capital LP bought a new position in ImageneBio in the 3rd quarter worth approximately $7,160,000. Blue Owl Capital Holdings LP purchased a new position in shares of ImageneBio in the third quarter worth $4,409,000. Atlas Venture Life Science Advisors LLC bought a new position in shares of ImageneBio during the third quarter worth $3,079,000. Vanguard Group Inc. purchased a new position in ImageneBio during the third quarter valued at $1,902,000. Finally, BML Capital Management LLC bought a new stake in ImageneBio in the 3rd quarter valued at $1,487,000. 75.00% of the stock is owned by hedge funds and other institutional investors.
About ImageneBio
(
Get Free Report)
ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
